Top

Published in:

01-10-2010 | Clinical trial

Prognostic factors for skeletal complications from metastatic bone disease in breast cancer

Authors: Janet E. Brown, Richard J. Cook, Allan Lipton, Luis Costa, Robert E. Coleman

Published in: Breast Cancer Research and Treatment | Issue 3/2010

Abstract

Skeletal morbidity is common in patients with bone metastases from breast cancer (BC) and can undermine patients’ functional independence and quality of life. Previously defined prognostic factors may not reflect current treatment standards and the use of antiresorptive therapies. We report a comprehensive multivariate analysis of potential prognostic factors for skeletal-related events (SREs) using data from a phase III, randomized study of zoledronic acid in patients with bone metastases from BC. The trial evaluated the number and timing of SREs (pathologic fracture, palliative radiotherapy to bone, surgery to bone to treat or prevent a fracture, and spinal cord compression) and assessed variables for prognostic significance in univariate and multivariate Cox-regression analyses. Continuous variables were categorized with predefined cutpoints. All associations with P < 0.05 were considered significant. A total of 444 zoledronic acid-treated patients with assessments of biochemical markers of bone metabolism and complete baseline variable data were included. Significant baseline prognostic factors for occurrence of a first SRE by multivariate analyses included age, pain score, prior history of an SRE, predominant lesion type, elevated bone-specific alkaline phosphatase, and lactate dehydrogenase. Prior fracture was found to be prognostic in a reduced multivariate analysis of time to first fracture, but not for time to first palliative radiotherapy. In conclusion, this model identified several prognostic factors that may be useful in routine clinical care. Validation of these factors in a separate dataset and generation of a prognostic risk score are recommended next steps.

Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176CrossRefPubMed

Coleman RE (1997) Skeletal complications of malignancy. Cancer 80(Suppl):1588–1594CrossRefPubMed

Major PP, Cook RJ, Chen BL et al (2005) Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic acid in patients with bone metastases from solid tumors. Support Cancer Ther 2:234–240CrossRefPubMed

Delea T, McKiernan J, Brandman J et al (2006) Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 4:341–347PubMed

Brown JE, Cook RJ, Major P et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59–69CrossRefPubMed

Coleman RE, Major P, Lipton A et al (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23:4925–4935CrossRefPubMed

Kohno N, Aogi K, Minami H et al (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23:3314–3321CrossRefPubMed

Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468PubMed

Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882CrossRefPubMed

10.

Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150–3157CrossRefPubMed

11.

Rosen LS, Gordon D, Tchekmedyian NS et al (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100:2613–2621CrossRefPubMed

12.

Brown JE, Thomson CS, Ellis SP et al (2003) Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89:2031–2037CrossRefPubMed

13.

Lipton A, Demers L, Curley E et al (1998) Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 34:2021–2026CrossRefPubMed

14.

Lipton A, Cook R, Saad F et al (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113:193–201CrossRefPubMed

15.

Patel B, DeGroot H (2001) Evaluation of the risk of pathologic fractures secondary to metastatic bone disease. Orthopedics 24:612–617 quiz 618-619PubMed

16.

Major PP, Cook RJ, Lipton A et al (2009) Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer 9:272CrossRefPubMed

17.

Kaminski M, Rosen LS, Gordon D et al (2005) Zoledronic acid is superior to pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications [poster]. Presented at primary therapy of early breast cancer 9th international conference; 26–29 January, 2005; St. Gallen, Switzerland. Abstract 107

18.

Rosen LS, Gordon D, Kaminski M et al (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377–387PubMed

19.

Rosen LS, Gordon DH, Dugan W Jr et al (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100:36–43CrossRefPubMed

20.

Kalbfleisch JD, Prentice RL (2002) The statistical analysis of failure time data. Wiley, New York, NY

21.

Lawless JF (2003) Statistical models and methods for lifetime data. Wiley, Hoboken, NJ

22.

Barton MB, Dawson R, Jacob S et al (2001) Palliative radiotherapy of bone metastases: an evaluation of outcome measures. J Eval Clin Pract 7:47–64CrossRefPubMed

23.

Hillner BE, Ingle JN, Chlebowski RT et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042–4057CrossRefPubMed

24.

Coleman RE, Brown J, Cook R (2008) Identification of serum lactate dehydrogenase (LDH) as a significant prognostic variable for survival: multivariate analysis in women with metastatic breast cancer (BC). Cancer Treat Rev 34(Suppl 1):28–29 Abstract P61CrossRef

25.

Jackson RD, Donepudi S, Mysiw WJ (2008) Epidemiology of fracture risk in the women’s health initiative. Curr Osteoporos Rep 6:155–161CrossRefPubMed

26.

Rosen LS, Gordon D, Kaminski M et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735–1744CrossRefPubMed

27.

Lipton A, Cook RJ, Major P et al (2007) Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 12:1035–1043CrossRefPubMed

Title: Prognostic factors for skeletal complications from metastatic bone disease in breast cancer
Authors: Janet E. Brown
Richard J. Cook
Allan Lipton
Luis Costa
Robert E. Coleman
Publication date: 01-10-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-0981-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2010

Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis

Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients

Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case–control study in Thai women

Gene amplification in ductal carcinoma in situ of the breast

Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer